Erythropoietin receptor peptide formulations and uses
First Claim
1. A method for treating a patient having chronic kidney disease (CKD), which method comprises administering once every 3 to 6 weeks to the patient a therapeutically effective amount of a compound according to Formula I that binds to and activates the erythropoietin receptor (EPO-R), wherein the therapeutically effective amount is a dosage of 0.25 to 1.25 milligram of the compound per 1 kilogram of body weight of the patient
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
-
Citations
8 Claims
- 1. A method for treating a patient having chronic kidney disease (CKD), which method comprises administering once every 3 to 6 weeks to the patient a therapeutically effective amount of a compound according to Formula I that binds to and activates the erythropoietin receptor (EPO-R), wherein the therapeutically effective amount is a dosage of 0.25 to 1.25 milligram of the compound per 1 kilogram of body weight of the patient
Specification